SWOG clinical trial number
CTSU/EA4181
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma
Open
Phase
II
Abbreviated Title
A Randomized 3-Arm Phase II Study Comparing 1.) BR/CR, 2.) BR/CR-A, and 3.) BR-A in Patients <= 70 Years Old w/ Untreated Mantle Cell Lymphoma
Status Notes
Activation - Effective 10/3/19
Activated
10/03/2019
Research committees
Lymphoma
Treatment
Rituximab
Bendamustine
Cytarabine
Eligibility Criteria Expand/Collapse
Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org ).
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA4181
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
10/03/2019
Open
Phase
II
SWOG Clinical Trial Number
S1826
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Activated
07/19/2019
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S1608
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/10/2017
Accrual
29%
Open
Phase